Neuropathic bladder dysfunction results from abnormal development of the spine, spinal cord injuries, or diseases such as diabetics. Patients with neuropathic bladders often require surgical intervention such as bladder reconstruction to improve incontinence and prevent renal damage. Tissue engineering with ex-vivo cultured bladder cells has been suggested as one means for improving bladder function. However, we previously demonstrated that cultured bladder smooth muscle cells (SMCs) derived from neuropathic bladder exhibit and maintain altered pathologic phenotypes in culture. To identify genes that are responsible for the abnormal neuropathic phenotypes specifically elevated cell proliferation, the expression levels of 1,185 genes were compared between cultured SMCs derived from normal and neuropathic bladders using a cDNA array consisting of well-annotated genes. The expression data were analyzed using several methods to identify differentially expressed genes. The resulting sets of differentially expressed genes were examined by pathway analysis to identify the networks that remain abnormal in the culture-stable phenotype of neuopathic SMCs. A total of 18 genes that are differentially expressed between cultured normal and neuropathic bladder SMCs were identified. Of these 17 were up-regulated greater than 2-fold in neuropathic bladder SMCs, six of them along with one gene that was not upregulated greater than 2-fold in cultured neuropathic bladder SMCs were confirmed and identified by more stringent analysis methods including significance analysis of microarrays, class comparison, and class prediction analyses. The major dysregulated pathways include fibroblast growth factor signaling, PTEN signaling, and integrin signaling. Our results further suggest that altered neuropathic bladder SMC phenotypes is stable in the culture environments and that SMCs derived from diseased bladders may not be appropriate for tissue engineering purpose without modification of pathologically altered genes expression.
Introduction
Patients with a neuropathic bladder have impaired bladder function resulting from damage to the nerves that control the urinary tract development and function (Keshtgar and Rickwood 1998) . In children, congenital spinal and neural tube defects of varying severity e.g. spina bifida occulta -meningocele -meningomyelocele -syringocele with associated myelodysplasia can result in a neuropathic bladder (van Gool et al., 2001) . Clinical problems associated with a neuropathic bladder include urinary incontinence, urinary infections, renal stones, upper urinary tract dilation (hydronephrosis), and renal deterioration (Mendizabal et al., 2005) . When patients develop progressive hydronephrosis or renal injury with a diminished bladder capacity, surgical reconstruction of the bladder in the form of bladder augmentation is often needed (Ahmed and Carney 1981) . Conventional augmentation is usually accomplished by placing a detubularized segment of intestine onto the neuropathic bladder (Mingin et al., 2002) . The deleterious side effects of the augmentation cystoplasty including infection, electrolyte abnormalities, stone formation, spontaneous perforation, and malignant tumor formation (Qiu et al., 2003) have ignited the field of tissue engineering in the hopes that a more appropriate form of treatment can be developed.
The specific biochemical, neuropharmacological, and histological features of the neuropathic bladder are largely unknown. A common feature of the neuropathic bladder is the thickening of the smooth muscle layer with hypertrophy and/or hyperplasia of detrusor smooth muscle cells (SMCs). The increase in muscle mass may result from the over distension of the bladder (Adam et al., 2004) . Elevated deposition of connective tissue within the muscle bundles is another major feature observed in the neuropathic bladder. Elevation in total collagens, preponderance of type III collagen, with marked interfascicular and pericellular infiltration has been demonstrated. The altered collagen expressions results in a significant increase in the type III/type I collagen ratio at both the mRNA and protein levels (Deveaud et al., 1998) , and affects both bladder architecture and function. However, the etiology of elevated cellular growth and increased collagens deposition in neuropathic bladder is unknown. It is also unclear whether the altered cellular growth and collagen deposition are the causes of abnormal histological, urodynamic, and functional abnormalities observed in neuropathic bladder. We demonstrated that primary cultures of bladder SMCs derived from neuropathic bladder exhibit elevated cell proliferation, reduced cell adherence, and decreased cell contractility as compared to cells obtained from a normal functional bladder . These observations are closely associated with clinical presentations of this bladder disease. To identify genes that are responsible for the altered phenotypes particularly elevated cell proliferation observed in cultured neuropathic bladder SMCs, we applied an array technique to compare transcripts expression between SMCs derived from normal and neuropathic bladder. Array analysis suggested that altered fibroblast growth factor (FGF), PTEN signaling, and integrin pathways may be responsible for elevated cell proliferation observed in neuropathic bladder SMCs. The development of cell-composite scaffold using patients' bladder cells for bladder tissue engineering is a popular approach since it might promote rapid bladder regeneration in vivo. However, our results suggest that cells derived from a diseased bladder may not be appropriate for direct use in tissue engineering and may require ex vivo modifications to correct some fundamental defects prior to re-insertion into the patient.
Materials and Methods

Materials and reagents
M199 medium, penicillin-streptomycin, and MEM vitamins were purchased from Invitrogen (Grand Island, NY). Fetal bovine serum (FBS) was acquired from Atlanta Biologicals (Norcross, Georgia). [μ-32P]dATP (3,000 Ci/mmol, 10 μCi/μl) was acquired from Amersham Pharmacia (Piscataway, NJ). Atlas Human Cancer 1.2 Array was obtained from Clontech (Palo Alto, CA). A total of 1,185 cDNAs are printed on the Atlas Human Cancer 1.2 Expression Array.
For the complete list of these genes see http://www.clontech.com/atlas/genelists/index.html.
Primary cultures of human bladder SMCs
In accordance with the University of Oklahoma Health Sciences Center's Institutional Review Board's approved protocol, bladder specimens were collected from two groups of patients: (1) patients who underwent open ureteral reimplantation for vesicoureteral reflux with otherwise normal bladder function, and (2) patients who underwent bladder augmentation and/ or other form of lower urinary tract reconstruction for neuropathic bladder. All patients with neuropathic bladder underwent flurovideourodynamics stuidies, and had severely trabeculated bladder on the flurovideourodynamics images. Urodynamics demonstrated that all patients with neuropathic bladder had small capacity, high pressure with poor compliance of the bladder wall, and impaired contractility. All of the patients demonstrated to have overactive bladders; but none of the specimens used for this study would be classified as underactive bladder. All patients had undergone maximal medical management with anticholinergic medications prior to consideration for bladder augmentation. Sample collection, processing, establishment of primary cultures, and subsequent subcultures were performed as previously described . The cells derived from expanded cultures were frozen at passage 3; and two additional passages were required to obtain sufficient cells for analysis after re-establishing the cultures from frozen cells. Gene expression profiling was analyzed for all bladder SMCs at passages 5.
Radio-labeled first-strand cDNA probe synthesis
Total RNA was extracted from cultured bladder SMCs using Trizol (Invitrogen). RNA quantity and quality was determined spectrophotometrically and formaldehyde/agarose gel electrophoresis, respectively. First-strand cDNA probes were reverse transcribed individually from each of the bladder SMC lines' total RNA. Reverse transcription was performed with 5 μg of total RNA, gene specific primers (CDS primers; Clontech), 35 μCi [α-32 P]-dATP, dCTP/ dGTP/dTTP, and 200 units Superscript II reverse transcriptase (Invitrogen) in a total of 10 μl at 42°C for one hour (Nunlist et al., 2004) . The labeling products were purified through the NucleoSpin Extraction Spin Columns (Clontech) to remove free nucleotides; and the radiolabeled first-strand cDNA probes were eluted with 100 μl elution buffer. Fractions (1 μl) of the [α- 32 P]-dATP-labeled cDNAs were counted with LS 6000IC scintillation counter (Beckman Coulter; Fullerton, CA) to determine radionucleotide incorporation.
Membrane array hybridization
The radiolabeled first-strand cDNA probes were hybridized to the Atlas Human Cancer 1.2 array membranes. This array emphasizes well-annotated cell cycle, apoptotic, signaling receptors, and matrix-related genes among others, and was chosen for the reason that changes in expression of these sets of genes would likely prove most fruitful in understanding the pathophysiology of neuropathic bladder. Membrane hybridization and data acquisition were performed as we previously described (Nunlist et al., 2004) . Briefly, the array membranes were prehybridized with 5 ml ExpressHyb TM solution (Clontech) in the presence of 0.5 μg denatured sheared salmon sperm DNA (Invitrogen) at 68°C for 30 minutes followed by the addition of heat-denatured [α-32 P]-dATP-labeled first-strand cDNA probes (20 × 10 6 cpm) and 5 mg Cot-1 DNA. Hybridization was performed at 68°C overnight. After hybridization, membranes were washed twice in 2X SSC plus 1% SDS at 68°C, followed by one wash in 0.1X SSC plus 0.5% SDS at 68°C and a final wash in 2X SSC at room temperature. Membranes were exposed to phosphor-imaging screens (Packard BioScience; Meriden, CT); and images were captured with the Cyclone storage phosphor imaging system (Packard BioScience). Results from the phosphor-imaging were presented as digital light units (DLU) and interpreted using the OptiQuant image analysis software (Packard BioScience).
Data normalization and analysis
Radioactive intensities of each array were log2-transformed and each array was normalized separately using the median of nine housekeeping genes [ubiquitin C (UBC; Genbank accession n u m b e r M 2 6 8 8 0 ) , p h o s p h o l i p a s e A 2 ( P L A 2 ; M 8 6 4 0 0 ) , h y p o x a n t h i n e -g u a n i n e phosphoribosyltransferase 1 (HPRT1; V00530), glyceraldehyde 3-phosphate dehydrogenases (GAPD; X01677), tubulin α1 (TUBA1; K00558), major histocompatibility complex class I C (HLAC; M11886), β-actin (ACTB; X00351), ribosomal protein L13A (RPL13A; X56932), and ribosomal protein S9 (RPS9; U14971)].
Identification of significant differences in gene expression between neuropathic and normal bladder SMC cultures: As with all array studies, distinguishing changes in gene expression that result from the biology rather than from those occurring randomly represents a challenge. Several procedures were adopted to minimize the false positives and the false negatives. Genes with a percentile of the log-ratio variation less than 75% were filtered out. This criterion identified the set of genes with the highest variability for further analysis on the assumption that genes showing low variability will not differ between the two classes. This filtering yielded 296 genes out of the 1,185 genes that were further analyzed using Biometric Research Branch (BRB) ArrayTools version 3.4.0 -Beta_2 software (http://linus.nci.nih.gov/BRBArrayTools.html), which is specifically designed for small microarray experiments (Wright and Simon 2003) . Differentially expressed genes were identified between cultured normal and neuropathic bladder SMCs using a univariate two-sample t-test with random variance model and significance threshold set to 0.001. A random variance model was selected to permit the sharing of information among arrays within class to eliminate the assumption that all of the arrays possess the same variance. With a 2-fold minimum difference in expression selected as significant, 17 genes were identified. More stringent analyses were also applied in which the number of false positives and false negatives could be estimated. These included class comparison, class prediction, and Significance Analysis of Microarray (SAM) algorithms, which were all implemented in the BRB ArrayTools. For class prediction and class comparison analyses, a random variance model was used with a significance level set to 0.001; and with SAM the false discovery rate was set to 0.1. These analyses all identified the same 7 genes, 6 of which were a subset of the 17 identified as being differentially expressed by 2-fold or more.
Pathway and transcriptional regulatory element (TRE) analysis: Finding common properties of a set of genes that are independent of their expression levels can begin to suggest biological mechanisms behind the expression patterns. The formation of networks representing reports of interactions among genes reported in the literature and in canonical pathways and commonalities of TREs in the upstream sequences were both used in this manner. Biologically relevant networks were assembled from the 17 genes that show two-fold or higher on their expression levels in neuropathic bladder SMCs using Ingenuity Pathways Analysis (IPA), a webbased expression analysis program (www.ingenuity.com). The IPA uses a genome-scale biological knowledge base and generates multiple biological networks with associated functional analysis. This analysis enables assembly and visualization of physical and functional direct and indirect interactions among a given gene set (focus genes) and other genes. Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. Genes were not weighted by expression levels; and biological networks were built on this assumption. Each network was assigned a significance score. Networks with score above 3.0 are considered significant at P<0.001 which cannot be explained by random chance alone. The functional analysis of networks identified the biological functions and/or diseases that are most significant to the genes in the network. Fischer's exact test was used to eliminate the probability that each biological function and/or disease assigned to that network is due to chance alone. Canonical pathways analysis identified the most significant pathways for a given set of genes. The significance that the results were obtained by random chance was measured by Fischer's exact test and the significance threshold was set to P<0.05.
The PAINT webtool identifies common upstream transcription factor binding sequences in a list of genes and compares the prevalence of sequences within the set to that expected by random chance (http://www.dbi.tju.edu/dbi/tools/paint/) (Vadigepalli et al., 2003) . PAINT was used to identify common transcription regulatory elements (TREs) shared by the 18 differentially expressed genes. In this analysis, the p values for significant enrichment of each TRE were calculated using hypergeometric distribution, by comparing the abundance of each TRE to that from a reference set of randomly selected genes. These estimates of significance were utilized in filtering for those TREs that meet a threshold (P<0.01) to identify common upstream sequences.
Semi-quantitative RT-PCR analysis
First-strand cDNA was reverse transcribed from 2.5 μg total RNA prepared from each of cultured normal and neuropathic bladder SMCs in the presence of 500 ng oligo (dT)12-18 primer (Invitrogen), 10 mM DTT, 300 μM each of dNTP, and 200 units of Superscript II reverse transcriptase at 42°C for 1 hour. Aliquots (1 μl) of the first-strain cDNAs were amplified in the presence of 0.2 μM each of basic FGF (bFGF, FGF2) or β-actin forward and reverse primers, 200 μM dNTP, 5 units of Taq DNA polymerase (Invitrogen) in a total of 50 μl. bFGF forward primer (5'-GTTGTGACAACCACAAGCAC-3') and reverse primer (5'-CTCTCACACTATCCACTGGT-3'); and β-actin forward primer (5'-CTTCTAGGCGGACTATGAC-3') and reverse primer (5'-ACTGCTGTCACCTTCACCGTTCCAGT-3'). β-Actin was amplified for each sample and used as an internal control. Reactions were first denatured at 94°C for 2 min; and amplification reactions were cycled through denaturation at 94°C for 30 seconds, annealing at 55°C for one minute, and elongation at 72°C for one minute for a total of 28-35 cycles. Aliquots (10 μl) of PCR amplified products were electrophoresized on 1.5% agarose gels. Images of ethidium bromide-stained gels were acquired with Gel Doc 1000 (Bio-Rad Laboratories, Hercules, CA); and band intensities were quantitated using Quantity One © image analysis software (Bio-Rad Laboratories). Results were expressed as ratios of bFGF:β-actin for each sample. A Student's t test was used to compare means of normalized bFGF expression between normal and neuropathic bladder SMCs.
Results
Gene expression patterns between cultured normal and neuropathic bladder SMCs
Phenotype averages of geometric means of cultured bladder SMCs derived from five control patients on the y axis versus the averages of cultured bladder SMCs derived from patients with neuropathic bladder on the x axis were plotted on log2-scale (Fig. 1) . Each gene was represented by a single point in the resulting scatter plot. Outlier lines indicate a two-fold difference between phenotype classes. The scatter plot of the 296 most variable genes present in the array showed a high degree of similarity between cultured bladder SMCs derived from normal and neuropathic bladders. However, we observed that cultured SMCs derived from neuropathic bladder tend to have slightly higher levels of expression for the majority of the genes analyzed (Fig. 1) .
Identification of altered genes expression in cultured neuropathic bladder SMCs
Differentially expressed genes were identified as greater than two-fold geometric means differences on the log2-scale between normal and neuropathic bladder SMCs. This identification was not statistically based, but served to identify a set of genes with a minimal level of altered expression. Among the 1,185 genes analyzed, levels of 17 (or 1.43%) of these genes were found to be expressed 2-fold or higher in the cultured neuropathic bladder SMCs as compared to cells derived from normal functional bladder (Table 1 ). Among these 17 identified genes, five genes (MT3, IIP9-27, CDK5R2, CGR19, and NUMA1) are involved in cell cycle regulation, two genes (TLK2 and CDKN1A) are involved in intracellular kinase networks, two genes (PCTP and AIF1) are involved in calcium binding, three interleukin genes (IL-5, IL-6, and IL-11), one growth factor gene (bFGF), and one G-protein gene (RAC1). Genes whose expression levels differed more than two-fold were clustered and visualized by GeneCluster and TreeView programs (Eisen et al., 1998) . Hierarchical clustering of the 17 genes showed that these genes largely separate neuropathic bladder SMCs from normal bladder SMCs (Fig. 2) . In contrast, there was one gene (IGFBP5) identified as being suppressed in cultured neuropathic bladder SMCs as compared to their counterparts derived from normal bladder (Table 1) .
With the filtered 296 genes, class comparison between two groups of bladder samples identified seven genes that are significantly differentially expressed between the SMCs derived from patients with normal and neuropathic bladders at P<0.001. SAM and the class comparison and prediction analyses of the 296 genes gave the same seven genes as differentially expressed between cultured normal and neuropathic bladder SMCs. One, however (CXCL13) did not show a two-fold difference. The other 6 are shown in bold in Table 1 . With 90th percentile confidence, the false discovery rate (FDR) among the seven significant genes is 0.07046. The delta value (another parameter for controlling FDR) used to identify the significant genes is 0.92673. The SAM plot for this comparison is shown in Fig. 3 . Furthermore, class prediction analysis identified the same seven genes as markers for the characterization of neuropathic bladder from a normal bladder (data not shown).
Identification of pathways potentially responsible for pathophysiology of neuropathic bladder SMCs
To understand whether the 17 genes up-regulated in neuropathic bladder SMCs can be correlated to previously defined signaling or metabolic pathways, the canonical pathway analysis was generated using the IPA. It identified pathways in which the 17 genes were significantly overrepresented as compared with genes randomly selected from reference gene list (the whole human genome taken from Ingenuity' Knowledge Base). In this analysis, genes involved in FGF signaling, PTEN signaling, and integrin signaling were significantly overrepresented in the cultured neuropathic bladder SMCs (Fig. 4) .
Gene networks of up-regulated genes in neuropathic bladder SMCs
In order to search for cellular pathways that may be responsible for pathophysiology of neuropathic bladder SMCs, we examined the 17 genes up-regulated in neuropathic bladder in known pathway networks. Among the 17 genes, 16 genes were mapped by the IPA; and two networks with scores above three were built from them ( Table 2 ). The first network, consisting of 13 of the 16 genes, regulates cell morphology, cellular assembly, as well as nervous system development and function. The second network, containing three remaining genes, is related to cell proliferation, cell cycle progression, cellular movement, and cell death. Known functional and physical interactions among the focus genes in the networks are shown in Fig. 5 . When the expression levels of the genes imputed by IPA were checked, all that were present on the array were actually expressed. 
Confirmation of the elevated bFGF mRNA expression in neuropathic bladder SMCs
Semi-quantitative RT-PCR was performed to confirm the difference in gene expression between cultured normal and neuropathic bladder SMCs. bFGF was expressed at higher levels in cultured neuropathic bladder SMCs as compared to normal bladder SMCs (Fig. 6) . The ratio of bFGF to β-actin expression was 0.71 ± 0.11 in neuropathic bladder SMCs versus 0.52 ± 0.07 in normal bladder SMCs; and levels of bFGF expression were statistically higher in neuropathic bladder SMCs (P<0.05).
Identification of TREs
TRE analysis performed for the 18 differentially expressed genes to identify biologically relevant TREs identified a total of 6 TREs as present, at least once, in the promoters of 7 genes among the 18 genes (Fig. 7) . TRAM1, IL-6, and VIM have the same TRE, hepatic leukemia factor (HLF). IL-11 and IGFBP5 share a common regulator, GATA-1, in the 5'-flanking regions of these genes. 
Discussion
The pathophysiology of the neuropathic bladder is poorly understood. In addition, there is no data indicating whether SMCs derived from the neuropathic bladder continue to possess aberrant phenotypes in culture. This study is to identify aberrant gene expression that is associated with the abnormal neuropathic bladder SMCs, and is highly relevant to the question of whether cultured bladder SMCs derived from the patients with neuropathic bladder can be used for the purpose of regenerating functional bladder. By analyzing levels of a group of well-annotated gene expressions, we sought to identify candidate genes and pathways that are associated with increased thickness of smooth muscle layers observed in neuropathic bladder and the elevated cell proliferation observed in cultured neuropathic bladder SMCs as compared to their normal counterparts . The selected cDNA microarray includes cytokines, growth factors, oncogenes, tumor suppressor genes, intracellular signaling, extracellular matrix proteins, and transcription factors that are responsible for abnormal cell growth and proliferation. Among the total of 1,185 genes analyzed, only 17 genes were identified to have at least two-fold increases in geometric means between SMCs derived from neuropathic and normal bladders ( Fig. 1 and Table 1 ). Of these, 6 genes passed a more rigorous statistical test for significance plus one gene that was less than 2-fold differentially expressed. The perfect mapping of these genes by Ingenuity into two networks supports the statistical significance of these genes between normal and neuropathic bladder SMCs (Table 2 and Fig. 5 ). We are conducting an experiment with wider array to identify genes that might be associated with other abnormalities such as decreased adhesion and contractility presented in cultured neuropathic bladder SMCs. Altered expression of growth factors can be implicated for the smooth muscle hypertrophy or hyperplasia observed in the neuropathic bladder. bFGF is a potent mitogenic factor in stimulating cell proliferation of multiple cell types including SMCs, fibroblasts, and endothelial cells (Hoshi et al., 2000; Thomas et al., 2003) . bFGF stimulates medial SMC proliferation following balloon catheter injury; and systemic administration of bFGF increases vascular SMC proliferation after injury (Lindner and Reidy, 1991) . Furthermore, bFGF causes a significant decrease in elastin mRNA expression in aortic SMC (Carreras et al., 2002) . Consistent with the Beqaj et al. (2005) also reported increased bFGF expression in cultured SMCs derived from neuropathic bladder, and bFGF has strong mitogenic effects on cultured bladder SMCs. Therefore, bFGF effects may be a component in the development of neuropathic bladder abnormality.
In addition to the well documented FGF pathway in regulating bladder SMC growth and proliferation, our array analysis suggested that PTEN and integrin signaling pathways may also be involved in the pathological development of neuropathic bladder SMCs. PTEN encodes a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway (Wu et al., 1998) as well as promotes cell survival and proliferation (Chang et al., 2003) . In addition to regulating the Akt/PKB pathway, PTEN interacts directly with focal adhesion kinase (FAK), and is able to dephosphorylate activated FAK (Haier and Nicolson, 2002) . FAK can also interact with integrins to regulate cell adhesion (Sawhney et al., 2006) . The interactions of PTEN, FAK, and integrins are responsible for regulating cell adhesion, spreading, and migration (Gu et al., 1998; Tamura et al., 1999) . PTEN also regulates matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase (TIMP) secretion (Park et al., 2002) may be involved in the regulation of extracellular matrix (ECM) composition. For example, fibronectin (FN) is a glycoprotein present at the cell surface and in ECM, and is involved in cell migration (Kang et al., 2004) , adhesion (Berrou and Bryckaert, 2001) , as well as cell proliferation (Giancotti and Ruoslahti, 1999) . These FN mediated physiological functions are tightly associated with integrins (Giancotti and Ruoslahti, 1999) . Since ECM composition can regulate smooth muscle proliferation and function (Fernandes et al., 2006) , poor compliant neuropathic bladder with altered ECM composition may modulate integrin signaling which, ultimately, regulate neuropathic bladder smooth muscle growth. The association between integrin signaling and elevated proliferation observed in cultured neuropathic bladder SMCs is consistent with results observed in other SMC types; the activation of integrin pathway has been consistently demonstrated in regulating a variety of SMC proliferation including airway SMCs (Nguyen et al., 2005) and vascular SMCs (Ling et al., 2005) . However, in contrast to our results, vascular SMCs, at least, seem to be grwoth-inhibited by active PTEN (Garl et al., 2004) . The differences between vascular SMC and bladder SMC suggested that the PTEN may be in an inactive form and indirectly upregulated in bladder SMCs, bladder SMCs are different from vascular SMCs, or the link between growth inhibition and PTEN is broken in neurogenic bladder.
Neurogenic bladder is the loss of normal bladder function caused by damage to part of the nervous system. Symptoms of neurogenic bladder range from detrusor underactivity to overactivity, depending on the site of neurological insult. FGF has been implicated in peripheral nervous system development and regeneration (Grothe et al., 2006) ; and PTEN has been implicated in the development of neurotubes (Li et al., 2003) . The relationship between these molecules and nerve development and function in neuropathic bladder remains unclear.
Roles of transcription factors in the development of neuropathic bladder has never been reported. We showed that differentially regulated gene expressions between cultured normal and neuropathic bladder SMCs share common TREs. For example, TRAM1, IL-6, and VIM can be commonly regulated by HLF (Fig. 7) . The transcription factor IRF-1, a regulator of interferons and a tumor suppressor, is highly regulated in human vascular lesions and exhibits a growth regulatory function in coronary artery SMCs (Wessely et al., 2003) . Glucocorticoid receptor (GR) has been shown to regulate rat vascular SMC (Kawai et al., 1998) and human prostatic stromal cells (Albrecht et al., 2002) proliferation. GR also up-regulates FN expression in human prostatic stromal cells (Albrecht et al., 2002) . Our findings suggested a common connection among differentially regulated genes could be linked to the indicated transcription factors in regulating neuropathic bladder SMC proliferation. More research will be needed to study whether transcription factors are also responsible for other abnormalities observed in neuropathic bladder SMCs such as adhesion and contractility.
Conclusion
We confirmed our previous observations that cultured neuropathic bladder SMCs are phenotypically different from SMCs derived from normal functional bladder based on gene expression patterns of these cells. More importantly, we identified candidate genes and pathways that might be responsible for elevated SMC growth observed in neuropathic bladder. Our results also demonstrated that SMCs derived from diseased bladder maintain altered phenotypes in culture. Further characterization of upstream regulator and downstream effector molecules of the identified genes is needed to better understand this bladder disease and to "correct" the abnormal phenotypes for the establishment of cell-composite scaffold for bladder tissue engineering.
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